Fill 1 Return To RT

View Table of Contents

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg case studies

Table of Contents

Chronic Postsurgical Posterior Uveitis With Macular Edema OS

Robert Sisk, MD

Chronic Posterior Uveitis, Irvine Gass Syndrome OD

Sabah Shah, MD

Chronic Birdshot Chorioretinopathy OU

Pouya Dayani, MD
Chronic Posterior Uveitis, Irvine Gass Syndrome OD image
Chronic Posterior Uveitis, Irvine Gass Syndrome OD image

Sponsored by EyePoint Pharmaceuticals

October 2021 Supplement | YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg case studies

Chronic Posterior Uveitis, Irvine Gass Syndrome OD

A Real-World Case Provided by Dr. Sabah Shah, Old Westbury, NY

Sabah Shah, MD

Sabah Shah, MD headshot

Share:

Initial Presentation

Patient demographics

76-year-old female

Relevant medical history

CE/IOL OD

Chief ocular complaint and duration of complaint

Decreased vision OD for more than 6 months

Relevant lab workup

FTA-ABS, Lyme titers, RPR, VDRL, TB test, HSV IgG+IgM, Toxoplasmosis, toxocariasis, HIV I+II, CMV IgM, ACE inhibitor, lysozyme, c-ANCA, p-ANCA, HLA-B27, HLA-B12, HLA-B51, HLA-A29, HLA-B7, HLA-DR 2. All negative

Diagnosis

Posterior uveitis of the right eye: Irvine Gass Syndrome

Previous treatments for ocular complaint

Monthly intravitreal corticosteroid suspension injection

Transitioned to short-duration intravitreal dexamethasone implants every 3 months

Additional comments

Decreased vision with increased edema of the right eye following a history of cataract surgery of the right eye

Reason to choose YUTIQ

Recurrent edema of the right eye that was responsive to shorter-acting intravitreal steroid agents

YUTIQ treatment

OD

Nine Months Follow-up After YUTIQ Treatment

How do you think this patient performed with YUTIQ?

The patient had a positive overall response to YUTIQ with resolution of edema and improved vision. The patient now has a long-acting medication for uveitis that allows for continuous localized inflammatory suppression without the need for recurrent intravitreal injections.

What are your future plans for this patient?

Currently, I see the patient every 4 to 6 months to monitor IOP and make sure there is no recurrence of posterior inflammation. I have no plans for any medical or surgical intervention at this time.

Case Imagery

<p>Figure 1a. Before YUTIQ Treatment OD: FA</p>

Click to view larger

Figure 1a. Before YUTIQ Treatment OD: FA

<p>Figure 1b. After 1 Month YUTIQ Treatment OD: FA</p>

Click to view larger

Figure 1b. After 1 Month YUTIQ Treatment OD: FA

<p>Figure 1c. After 9 Months YUTIQ Treatment OD: FA</p>

Click to view larger

Figure 1c. After 9 Months YUTIQ Treatment OD: FA

<p>Figure 2a. Before YUTIQ Treatment OD: OCT</p>

Click to view larger

Figure 2a. Before YUTIQ Treatment OD: OCT

<p>Figure 2b. After 1 Month YUTIQ Treatment OD: OCT</p>

Click to view larger

Figure 2b. After 1 Month YUTIQ Treatment OD: OCT

<p>Figure 2c. After 1 Month YUTIQ Treatment OD: OCT</p>

Click to view larger

Figure 2c. After 1 Month YUTIQ Treatment OD: OCT

ACE=angiotensin converting enzyme; ANCA= antineutrophil cytoplasmic antibodies; BCVA=best corrected visual acuity; CE=cataract extraction; CMV=cytomegalovirus; FTA-ABS=fluorescent treponemal antibody absorption; HIV=human immunodeficiency virus; HLA=human leukocyte antibody; HSV=herpes simplex virus; IgG=immunoglobulin G; IgM=immunoglobulin M; IOL=intraocular lens; IOP=intraocular pressure; RPR=rapid plasma regain; TB=tuberculosis; VDRL=venereal disease research laboratory test.

Sabah Shah, MD headshot

Sabah Shah, MD

Vitreoretinal Surgery
Retina Group of New York

Assistant Professor of Ophthalmology
Albany Medical Center

Next Article in this Supplement

Chronic Birdshot Chorioretinopathy OU

Pouya Dayani, MD

View Article Fill 1

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg case studies

Table of Contents

Chronic Postsurgical Posterior Uveitis With Macular Edema OS

Robert Sisk, MD

Chronic Posterior Uveitis, Irvine Gass Syndrome OD

Sabah Shah, MD

Chronic Birdshot Chorioretinopathy OU

Pouya Dayani, MD

YUTIQ and the YUTIQ logo are registered trademarks of EyePoint Pharmaceuticals, Inc.

©2021 EyePoint Pharmaceuticals, Inc. All rights reserved.

480 Pleasant Street, Suite B300, Watertown, MA 02472

09/2021 US-YUT-2100114

Important Safety Information

See More +

INDICATIONS AND USAGE

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

Hypersensitivity: YUTIQ is contraindicated in patients with known hypersensitivity to any components of this product.

WARNINGS AND PRECAUTIONS

Intravitreal Injection-related Effects: Intravitreal injections, including those with YUTIQ, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection.

Steroid-related Effects: Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.

Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

ADVERSE REACTIONS

In controlled studies, the most common adverse reactions reported were cataract development and increases in intraocular pressure.

Please see full Prescribing Information at YUTIQ.com.